Genuity Science’s approach combines high-quality, whole-genome sequence and deep phenotype data resulting in better definition of the underlying disease mechanisms. This approach, when coupled with Ionis’ proprietary antisense technology, has the potential to significantly expedite the drug development process through a more direct translation of targets into therapeutics.
Under terms of the multi-year collaboration, Genuity Science will receive a combination of upfront payments and development milestones, plus product royalties.
“Ionis’ financial strength and the success of our validated antisense technology have positioned us to invest in new technologies that enhance our R&D capabilities,” said Brett P. Monia, Ph.D., chief executive officer of Ionis. “The collaboration with Genuity Science gives us the potential to significantly increase our discovery opportunities and better understand the complexities of human diseases based on genetics.”
“We are excited to collaborate with an innovative company like Ionis,” said Rob Brainin, chief executive officer of Genuity